Insulet (PODD) Liabilities and Shareholders Equity (2010 - 2026)
Insulet (PODD) posted Liabilities and Shareholders Equity of $3.0 billion for Q1 2026, down 6.37% on a QoQ basis from $3.2 billion in Q4 2025, and down 15.07% year-over-year from $3.5 billion in Q1 2025.
Insulet (PODD) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Insulet's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $3.0 billion for Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 15.07% year-over-year to $3.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.7 billion (up 1.31% YoY) and the FY2025 annual result came in at $3.2 billion, up 3.33% from the prior year.
- Liabilities and Shareholders Equity was $3.0 billion for Q1 2026 at Insulet, down from $3.2 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $3.5 billion in Q1 2025 and bottomed at $2.1 billion in Q1 2022.
- A 5-year average of $2.7 billion and a median of $2.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity soared 34.04% — and 2026, when it decreased 15.07%.
- Insulet's Liabilities and Shareholders Equity stood at $2.3 billion in 2022, then increased by 14.97% to $2.6 billion in 2023, then rose by 19.3% to $3.1 billion in 2024, then grew by 3.33% to $3.2 billion in 2025, then decreased by 6.37% to $3.0 billion in 2026.
- Business Quant data shows PODD's Liabilities and Shareholders Equity at $3.0 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 6.63 Bn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 37.13 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | 10.46 Bn |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 31.92 Bn |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | 2.99 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.99 Bn |
| Dec 31, 2025 | 3.19 Bn |
| Sep 30, 2025 | 3.03 Bn |
| Jun 30, 2025 | 3.47 Bn |
| Mar 31, 2025 | 3.52 Bn |
| Dec 31, 2024 | 3.09 Bn |
| Sep 30, 2024 | 3.03 Bn |
| Jun 30, 2024 | 2.88 Bn |
| Mar 31, 2024 | 2.62 Bn |
| Dec 31, 2023 | 2.59 Bn |
| Sep 30, 2023 | 2.47 Bn |
| Jun 30, 2023 | 2.39 Bn |
| Mar 31, 2023 | 2.29 Bn |
| Dec 31, 2022 | 2.25 Bn |
| Sep 30, 2022 | 2.17 Bn |
| Jun 30, 2022 | 2.11 Bn |
| Mar 31, 2022 | 2.07 Bn |
| Dec 31, 2021 | 2.05 Bn |
| Sep 30, 2021 | 2.00 Bn |
| Jun 30, 2021 | 1.92 Bn |